Erudio Healtherudio.com
Clinical trial · no report yet · Phase 3
PRESTO trial (apalutamide): what clinicians have said so far
A Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer
- NCT03009981 ↗
- Completed
- Alliance Foundation Trials, LLC.
- Standard size, estimated: 151–300 verified statements once built
We haven't built an HCP commentary report on PRESTO (apalutamide; apalutamide plus abiraterone in high-risk biochemically relapsed castration-sensitive prostate cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on PRESTO so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 11 posts on X, typically up to 48 once built | |
| 2 podcast episodes, typically up to 9 once built | |
| 1 YouTube video, typically up to 4 once built |
The trial
ClinicalTrials.gov- Official title
- A Phase 3 Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer
- Phase
- Phase 3
- Status
- Completed
- Conditions
- Prostate Cancer
- Interventions
- Apalutamide; LHRH Analogue; Abiraterone Acetate; Prednisone
- Arms
- Arm A: Degarelix Monotherapy OR Leuprolide/Bicalutamide · Active comparator
- Arm B: Degarelix/Apalutamide · Experimental
- Arm C: Degarelix/Apalutamide/Abiraterone/Prednisone · Experimental
- Enrollment
- 503
- Primary outcomes
- PSA Progression-free Survival in the Intent-to-treat Population
- Sponsor
- Alliance Foundation Trials, LLC. with Janssen Research & Development, LLC
- Start
- Mar 6, 2017
- Primary completion
- Jun 25, 2025
- Results posted
- Yes
- Registry record
- NCT03009981 · updated Nov 9, 2026
Publications
linked from the registry- Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015 Jan-Feb;65(1):5-29. doi: 10.3322/caac.21254. Epub 2015 Jan 5. PubMed 25559415
- Zietman AL, Chung CS, Coen JJ, Shipley WU. 10-year outcome for men with localized prostate cancer treated with external radiation therapy: results of a cohort study. J Urol. 2004 Jan;171(1):210-4. doi: 10.1097/01.ju.0000100980.13364.a6. PubMed 14665878
- Humphrey PA, Moch H, Cubilla AL, Ulbright TM, Reuter VE. The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part B: Prostate and Bladder Tumours. Eur Urol. 2016 Jul;70(1):106-119. doi: 10.1016/j.eururo.2016.02.028. Epub 2016 Mar 17. PubMed 26996659
- Zelefsky MJ, Ben-Porat L, Scher HI, Chan HM, Fearn PA, Fuks ZY, Leibel SA, Venkatraman ES. Outcome predictors for the increasing PSA state after definitive external-beam radiotherapy for prostate cancer. J Clin Oncol. 2005 Feb 1;23(4):826-31. doi: 10.1200/JCO.2005.02.111. PubMed 15681527
- Qu Y, Dai B, Ye D, Kong Y, Chang K, Jia Z, Yang X, Zhang H, Zhu Y, Shi G. Constitutively active AR-V7 plays an essential role in the development and progression of castration-resistant prostate cancer. Sci Rep. 2015 Jan 7;5:7654. doi: 10.1038/srep07654. PubMed 25563505
- Gershon RC, Rothrock N, Hanrahan R, Bass M, Cella D. The use of PROMIS and assessment center to deliver patient-reported outcome measures in clinical research. J Appl Meas. 2010;11(3):304-14. PubMed 20847477
- Morgan TM, Boorjian SA, Buyyounouski MK, Chapin BF, Chen DYT, Cheng HH, Chou R, Jacene HA, Kamran SC, Kim SK, Kirkby E, Luckenbaugh AN, Nathanson BJ, Nyame YA, Posadas EM, Tran PT, Chen RC. Salvage Therapy for Prostate Cancer: AUA/ASTRO/SUO Guideline Part III: Salvage Therapy After Radiotherapy or Focal Therapy, Pelvic Nodal Recurrence and Oligometastasis, and Future Directions. J Urol. 2024 Apr;211(4):526-532. doi: 10.1097/JU.0000000000003890. Epub 2024 Feb 29. PubMed 38421252
- Aggarwal R, Heller G, Hillman DW, Xiao H, Picus J, Taplin ME, Dorff T, Appleman L, Weckstein D, Patnaik A, Bryce A, Shevrin D, Mohler J, Anderson D, Rao A, Tagawa S, Tan A, Halabi S, Dooley K, O'Brien P, Chen R, Ryan CJ, Eggener SE, Morris MJ; EORTC-55994 Study Group. PRESTO: A Phase III, Open-Label Study of Intensification of Androgen Blockade in Patients With High-Risk Biochemically Relapsed Castration-Sensitive Prostate Cancer (AFT-19). J Clin Oncol. 2024 Apr 1;42(10):1114-1123. doi: 10.1200/JCO.23.01157. Epub 2024 Jan 23. PubMed 38261983